P53 is correlated with low BMI negative progesterone receptor status and recurring disease in patients with endometrial cancer

Gynecologic Oncology

Volumn 125, Issue 1, 2012, Pages 200-207

  Seeger, A ^a   Kolbl H ^a   Petry, I B ^a   Gebhard, S ^a   Battista, M J ^a   Bohm D ^a   Steiner, E ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Department of Gynecology and Obstetrics GP Ruesselsheim ^*  (Germany)

Author keywords

Endometrial cancer; p53; Phospho p53

Indexed keywords

PHOSPHOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53;

AGED; ARTICLE; BODY MASS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM CANCER; FEMALE; FISHER EXACT TEST; HUMAN; IMMUNOHISTOCHEMISTRY; LOG RANK TEST; MEDICAL RECORD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RANK SUM TEST; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; BODY MASS INDEX; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; DISEASE-FREE SURVIVAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, P53; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROGNOSIS; RECEPTORS, PROGESTERONE; RECURRENCE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84858342156     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.12.443     Document Type: Article

References (40)

1. F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, and I. Vergote Endometrial cancer Lancet 366 2005 491 505 (Pubitemid 41111699)
2. L.S. Ulrich Endometrial cancer, types, prognosis, female hormones and antihormones Climacteric 14 4 2011 418 425
3. D.S. Miller, and L.P. King Gynecologic oncology group trials in uterine corpus malignancies: recent progress J Gynecol Oncol 19 2008 218 222
4. E. Steiner, O. Eicher, J. Sagemuller, M. Schmidt, H. Pilch, and B. Tanner Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University Int J Gynecol Cancer 13 2003 197 203 (Pubitemid 37055478)
5. B. Vogelstein, D. Lane, and A.J. Levine Surfing the p53 network Nature 408 2000 307 310
6. P. Hainaut The tumor suppressor protein p53: a receptor to genotoxic stress that controls cell growth and survival Curr Opin Oncol 7 1995 76 82
7. W.E. Mercer, C. Avignolo, and R. Baserga Role of the p53 protein in cell proliferation as studied by microinjection of monoclonal antibodies Mol Cell Biol 4 1984 276 281
8. C.A. Finlay, P.W. Hinds, and A.J. Levine The p53 proto-oncogene can act as a suppressor of transformation Cell 57 1989 1083 1093 (Pubitemid 19169804)
9. K.M. Ryan, A.C. Phillips, and K.H. Vousden Regulation and function of the p53 tumor suppressor protein Curr Opin Cell Biol 13 2001 332 337 (Pubitemid 32429498)
10. W.S. el-Deiry Regulation of p53 downstream genes Semin Cancer Biol 8 1998 345 357 (Pubitemid 29131356)
11. A.J. Levine, J. Momand, and C.A. Finlay The p53 tumour suppressor gene Nature 351 1991 453 456 (Pubitemid 21896613)
12. A. Sigal, and V. Rotter Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome Cancer Res 60 2000 6788 6793 (Pubitemid 32059139)
13. M.F. Kohler, A. Berchuck, A.M. Davidoff, P.A. Humphrey, R.K. Dodge, and J.D. Iglehart Overexpression and mutation of p53 in endometrial carcinoma Cancer Res 52 1992 1622 1627
14. N. Sakuragi, H. Watari, Y. Ebina, R. Yamamoto, E. Steiner, and H. Koelbl Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer Int J Cancer 116 2005 514 519 (Pubitemid 41099186)
15. E.J. Lee, T.J. Kim, D.S. Kim, C.H. Choi, J.W. Lee, and J.H. Lee p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review Gynecol Oncol 116 2010 533 538
16. S. Ozalp, O.T. Yalcin, H.M. Tanir, S. Kabukcuoglu, and G. Erol p53 overexpression as a prognostic indicator in endometrial carcinoma Eur J Gynaecol Oncol 24 2003 275 278 (Pubitemid 36644615)
17. M.A. Osmanagaoglu, S. Kadioglu, S. Osmanagaoglu, H. Bozkaya, A. Reis, and Y. Tekelioglu The relationship between mutant p53 gene, DNA contents and conventional clinicopathological prognostic variables in cases with endometrial carcinoma Eur J Gynaecol Oncol 26 2005 64 70 (Pubitemid 40314071)
18. K. Ito, K. Watanabe, S. Nasim, H. Sasano, S. Sato, and A. Yajima Prognostic significance of p53 overexpression in endometrial cancer Cancer Res 54 1994 4667 4670 (Pubitemid 24276491)
19. Y.T. Jeon, S. Kang, D.H. Kang, K.Y. Yoo, I.A. Park, and Y.J. Bang Cyclooxygenase-2 and p53 expressions in endometrial cancer Cancer Epidemiol Biomarkers Prev 13 2004 1538 1542 (Pubitemid 39202324)
20. A. Koul, A. Borg, T. Pejovic, P.O. Bendahl, T. Hogberg, and C.S. Iosif Identification of TP53 gene mutations in uterine corpus cancer with short follow-up Gynecol Oncol 67 1997 295 302 (Pubitemid 28034637)
21. W.T. Creasman, F. Odicino, P. Maisonneuve, U. Beller, J.L. Benedet, and A.P. Heintz Carcinoma of the corpus uteri J Epidemiol Biostat 6 2001 47 86
22. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem 72 1976 248 254
23. O. Erdem, M. Erdem, A. Dursun, G. Akyol, and A. Erdem Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables Int J Gynecol Pathol 22 2003 254 260 (Pubitemid 36750407)
24. N. Sakuragi, A. Hirai, M. Tada, H. Yamada, R. Yamamoto, and S. Fujimoto Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma Gynecol Oncol 83 2001 485 490 (Pubitemid 33139708)
25. H. Battifora p53 immunohistochemistry: a word of caution Hum Pathol 25 1994 435 437 (Pubitemid 24173858)
26. P. Kohlberger, C. Kainz, G. Breitenecker, G. Gitsch, G. Sliutz, and H. Kolbl Prognostic value of immunohistochemically detected p53 expression in vulvar carcinoma Cancer 76 1995 1786 1789
27. M.E. Sherman, M.E. Bur, and R.J. Kurman p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis Hum Pathol 26 1995 1268 1274
28. S.F. Lax, B. Kendall, H. Tashiro, R.J. Slebos, and L. Hedrick The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways Cancer 88 2000 814 824 (Pubitemid 30091101)
29. D.B. Woods, and K.H. Vousden Regulation of p53 function Exp Cell Res 264 2001 56 66 (Pubitemid 32989081)
30. T. Buschmann, T. Minamoto, N. Wagle, S.Y. Fuchs, V. Adler, and M. Mai Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability J Mol Biol 295 2000 1009 1021
31. K. Maeda, H. Tsuda, Y. Hashiguchi, K. Yamamoto, T. Inoue, and O. Ishiko Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer Hum Pathol 33 2002 386 391 (Pubitemid 34627588)
32. I.B. Engelsen, I. Stefansson, L.A. Akslen, and H.B. Salvesen Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas Am J Obstet Gynecol 195 2006 979 986 (Pubitemid 44415644)
33. P. Strang, B. Nordstom, S. Nilsson, R. Bergstrom, and B. Tribukait Mutant p53 protein as a predictor of survival in endometrial carcinoma Eur J Cancer 32A 1996 598 602
34. A. Koul, P.O. Bendahl, A. Borg, M. Ferno, M.F. Lidebring, and T. Hogberg TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer Int J Gynecol Cancer 12 2002 362 371 (Pubitemid 34839834)
35. S.S. Wachtel, G. Wachtel, L.P. Shulman, O. Phillips, B. Miller, and G. Photopulos Identification of p53 mutations in endometrial adenocarcinoma by polymerase chain reaction-single-strand conformation polymorphism J Soc Gynecol Investig 1 1994 234 237 (Pubitemid 2134393)
36. H.C. Shih, T. Shiozawa, K. Kato, T. Imai, T. Miyamoto, and J. Uchikawa Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator Hum Pathol 34 2003 471 478 (Pubitemid 36666813)
37. C. Suzuki, T. Matsumoto, H. Sonoue, A. Arakawa, Y. Furugen, and K. Kinoshita Prognostic significance of the infiltrative pattern invasion in endometrioid adenocarcinoma of the endometrium Pathol Int 53 2003 495 500 (Pubitemid 37076289)
38. J. Dupont, X. Wang, D.S. Marshall, M. Leitao, C.V. Hedvat, and A. Hummer Wilms tumor gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray Gynecol Oncol 94 2004 449 455 (Pubitemid 39024552)
39. K.K. Mauland, J. Trovik, E. Wik, M.B. Raeder, T.S. Njolstad, and I.M. Stefansson High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer Br J Cancer 104 2011 921 926
40. H.S. Seo, J.H. Ju, K. Jang, and I. Shin Induction of apoptotic cell death by phytoestrogens by up-regulating the levels of phospho-p53 and p21 in normal and malignant estrogen receptor alpha-negative breast cells Nutr Res 31 2011 139 146